Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It provides long‑acting contraception by preventing ovulation and creating a uterine environment that is unfavorable for fertilization and implantation in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each shipment. Customers receive technical support and training for proper insertion and follow‑up care.

Jaydess, a levonorgestrel intrauterine system, is used within the contraceptive pathway to prevent pregnancy.

Contraception (general): prevents pregnancy for up to three years in women of reproductive age. Post‑abortion contraception: provides reliable birth control immediately after a therapeutic abortion. Post‑partum contraception: offers effective contraception following childbirth while allowing breastfeeding.

Jaydess may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or cramping pain after insertion - Breast tenderness - Headache - Nausea

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Pelvic inflammatory disease or infection - Ectopic pregnancy if contraception fails - Severe allergic reaction (anaphylaxis)

Before prescribing Jaydess, clinicians should evaluate several safety considerations.

Screen for pregnancy: confirm the patient is not pregnant prior to insertion. Assess uterine anatomy: avoid use in patients with known uterine anomalies or fibroids that may impede placement. Check for active infection: postpone insertion if pelvic infection is present. Counsel on bleeding changes: inform patients that spotting or amenorrhea are common. Avoid in known hypersensitivity: do not use if the patient has a documented allergy to levonorgestrel or device components. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Jaydess can be affected by certain concomitant medicines.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Rifampin and other strong CYP3A4 inducers: can lower levonorgestrel levels and increase risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline): may slightly decrease hormone effectiveness. - Antiretroviral agents (e.g., efavirenz): may reduce levonorgestrel concentrations. - Herbal supplements such as St. John’s wort: can increase hormone metabolism and diminish contraceptive reliability.